Jun 08, 2021 / 06:10PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
And I believe we're live, if I counted down in my head correctly. Hello, everyone, good afternoon. My name is Chris Shibutani. I'm a member of the Goldman Sachs biotech equity research team now apparently. I'm joined by my colleague, CJ Zopf. CJ, wave to your fans.
Christopher John Zopf - Cowen and Company, LLC, Research Division - Former Associate
Hello there.
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
We're here together with Nektar Therapeutics. We're very excited to have joining us today, Jennifer Ruddock, Senior Vice President of Strategy and Corporate Affairs, different shop, but I'll continue my tradition, CFO, Gil Labrucherie, which we'll just call you Gil for short; and of course, everybody knows JZ as well, Jonathan Zalevsky, who's beaming down from his location to join us so that he can tackle all the tough questions that CJ always asks so politely.
So we're excited to get to
Nektar Therapeutics at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers